Alissa Marr is an Oncology physician affiliated with University of Nebraska Medical Center. OpenAlex indexes 66 publications with 1,031 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 S 45th St
Omaha, NE 681981850
Telephone
402-559-5600Registry record last updated 23 Oct 2019.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Delcath SystemsProgram year20251 payment
- Iovance Biotherapeutics, Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.7%Mitogen-activated protein kinase (MEK) inhibitors18.2%Mektovi100%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors16.8%Braftovi100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
15.4%l-Thyroxine15.4%Levothyroxine Sodium100%Part D<11 patientsMetabolism & gastrointestinal
13.3%Corticosteroid13.3%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MDS-1181: Epidemiological Insights Into Chronic Myelomonocytic Leukemia: A Real-World Evidence Study Using the TriNetX Network
Clinical Lymphoma Myeloma & Leukemia
2025 - NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study
Anticancer Research
2024
Similar KOLs
Other experts from the same institution or the same specialty.
James Armitage, MD
University of Nebraska Medical Center
Julie Vose, MD
University of Nebraska Medical Center
Kathleen Moore, MD
University of Nebraska Medical Center
Ted Mikuls, MD
University of Nebraska Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”